We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · May 26, 2021

ACC 2021: Dapagliflozin Safe in Patients With Cardiometabolic Risk Factors Hospitalized for COVID-19

Nonsignificant trends suggesting benefits of this drug were observed in the DARE-19 trial

PracticeUpdate Editorial Team

 

Further Reading